NOV 1 7 2006

PTO/SB/21 (09-06) Approved for use through 03/31/2007. OMB 0651-0031

المارة ا U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL	Application Number	10/587,678
TRANSMITTAL	Filing Date	July 27, 2006
FORM	First Named Inventor	10/587,678
	Art Unit	Unknown
(to be used for all correspondence after initial filing)	Examiner Name	Ųnknown
Total Number of Pages in This Submission	Attorney Docket Number	01435.035US1
	· · · · · · · · · · · · · · · · · · ·	

Total Number	Trages in This Submission			
		ENCLOSURES (Check	all that appl	y)
Amendar  Amendar  Extension  Express  Informati  Certified Docume  Reply to Incomple	nsmittal Form Fee Attached nent/Reply After Final Affidavits/declaration(s) on of Time Request Abandonment Request ion Disclosure Statement Copy of Priority nt(s) Missing Parts/ ete Application Reply to Missing Parts	Drawing(s)  Licensing-related Papers  Petition Petition to Convert to a Provisional Application Power of Attorney, Revoca Change of Correspondence Terminal Disclaimer Request for Refund  CD, Number of CD(s)  Landscape Table on  Remarks	ation e Address	After Allowance Communication to TC  Appeal Communication to Board of Appeals and Interferences  Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter Other Enclosure(s) (please Identify below):  Form 1449 (1 pg.); Copies of 26 cited references; Return Postcard
	Inder 37 CFR 1.52 or 1.53	TURE OF APPLICANT, ATT	ORNEY,	OR AGENT
Signature				
Printed name Robert J. Harris				
Date	November <u>/ /</u> , 2006		Reg. No.	37,346
I hereby certify the sufficient postage the date shown to Signature	nat this correspondence is be as first class mail in an en pelow:	velope addressed to: Commissioner	PTO or depo	ILING sited with the United States Postal Service with P.O. Box 1450, Alexandria, VA 22313-1450 on
oignatule -	Olma	a Man		

November 24, 2006 Date Lynda Mau Typed or printed name This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

XN 10/587,678

**PATENT** 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

NOV 1 7 2006, pplicant:

Kathryn E. Uhrich et al.

Examiner:

Docket:

Unknown

Sérial No.:

10/587,678

Group Art Unit:

Unknown

TO TRADEN iled: Title:

July 27, 2006

01435.035US1

AMPHIPHILIC STAR-LIKE OR SCORPION-LIKE MACROMOLECULES, VARIOUS

**COMPOSITIONS AND USES THEREOF** 

## INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. § 1.97, no fee or statement is required with the Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 503503 in order to have this Information Disclosure Statement considered. The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

> Respectfully submitted, Kathryn E. Uhrich et al. By their Representatives, Viksnins Harris & Padys PLLP P.O. Box 111098 St. Paul, MN 55111-1098 952 876-4094

Robert J. Harris Reg. No. 37,346

CERTIFICATE UNDER 37 CFR 1.8: I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment; Commissioner for Patents; P.O. Box 1450, Alexandria, VA 22313-1450, on this 14 day of November 2006.

Substitute for form 1449A/PTO and/or 1449B/PTO		Complete if Known		
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/587,678	
	(Use as many sheets as necessary)	Filing Date	07/27/06	
	1 200° × 7 200°	First Named Inventor	Kathryn E. Uhrich	
	NOV 1 7 2006 g)	Group Art Unit	Unknown	
18		Examiner Name	Unknown	
	Sheet 1 of 1	Attorney Docket No: 01435.035US1		

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Foreign Document Number (include country code)	Publication Date	Translation (Abstract Only or Full Translation, if applicable)	
	WO 03/103594	Dec. 18, 2003		
	WO 03/005959	Jan. 23, 2003		
7: F	WO 00/65024	Nov. 2, 2000		
	WO 03/103594	Dec. 18, 2003	-	

	OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner		
Initials*	(book, magazine, journal, serial, symposium, catalog, etc.), <u>Volume-Number</u> , page(s) and (date).	
	International PCT Search Report for PCT/US 05/002900, (08/08/2005), 5 pgs.	
· · · · · · · · · · · · · · · · · · ·	Allen et al., Colloids Surf., B: Biointerfaces (1999) 16:3-27.	
	Camejo et al., Atherosclerosis Supplements, (2002) 3:3-9.	
	Cammas et al., Macromol. Chem. Phys. (1995) 196:1899-1905.	
-	Chnari et al., Biomaterials, (2005) 26:3749-3758.	
	Djordjevic, J. et al. AAPS Pharmsci (2003) 5(4):1-12.	
	Gao et al., Macromolecules, (1993) 26:7353-7360.	
	Gitsov et al., J. Polym. Sci., Part A: Polym. Chem. (2000) 38:2711-2727.	
_	Kreig et al., J. Chem. Phys. (2001) 115:6243-6251.	
	Liu, H. et al. J. Polymer Sci.: Part A: Polymer Chem. (1999) 37:703-711.	
	Moghimi et al., J. Pharm. Rev. (2001) 53(2):283-318.	
	Moghimi, S. M., Adv. Drug Delivery Rev. (1995) 17:1.	
	Moore, J.S. et al. Macromolecules (1990) 23(1):65-70.	
	Otsuka et al., Curr. Opin. Colloid Interface Sci. (2001) 6:3-10.	
	Papisov, Adv. Drug Delivery Rev. (1995) 16:127-139.	
	Rousselle C., et al., Mol. Pharmacol. (2000) 57(4):679-686.	
	Schmalenberg et al., Biomacromolecules (2001) 2:851-855.	
	Temsamani, et al., PSTT, (2000) 3(5):155-162.	
	Tian et al., Macromolecules, (2004) 37:538-543.	
<u> </u>	Tian, L. "Novel Amphiphilic macromolecules for drug delivery applications: Design,	
	Synthesis and Characterization" in Dissertation, New Brunswick, New Jersey (2004),	
	pp. 13-48, 114-138, 160-175.	
	Wiliams et al., Arteriosclerosis, Thrombosis & Vascular Biology, (1995) 15(5):551-	
	561.	
	Zhu et al., J. Polym. Sci. Polm. Chem., (1989) 27,:2151.	

**EXAMINER** 

DATE CONSIDERED